Literature DB >> 18552156

Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.

Yanli Song1, Laura Coleman, Jianru Shi, Hideyuki Beppu, Kaori Sato, Kenneth Walsh, Joseph Loscalzo, Ying-Yi Zhang.   

Abstract

Heterozygous bone morphogenetic protein receptor-II-knockout (BMPR2(+/-)) mice have a similar genetic trait like that in some idiopathic pulmonary arterial hypertension patients. To examine the effect of pulmonary endothelial injury in BMPR2(+/-) mice, we challenged the mice with two injections of monocrotaline combined with intratracheal instillation of replication-deficient adenovirus expressing 5-lipoxygenase (MCT+Ad5LO). After the challenge (1 wk), BMPR2(+/-) mice exhibited a doubling of right ventricular systolic pressure that was greater than that of wild-type mice and remained elevated for 3 wk before heart failure developed. Muscularization and thickening of small pulmonary arterioles was evident in the BMPR2(+/-) lungs at 2 wk after the challenge and became severe at 3 wk. Marked perivascular infiltration of T cells, B cells, and macrophages was associated with the remodeled vessels. Real-time PCR analysis showed that the expression of six endothelial cell markers in lung tissue was decreased to 20-40% of original levels at 1 wk after the challenge in both BMPR2(+/-) and wild-type mice and largely recovered in wild-type (50-80%) but not BMPR2(+/-) lungs (30-50%) at 3 wk after the challenge. Macrophage inflammatory protein-1alpha and fractalkine receptor expression doubled in BMPR2(+/-) compared with wild-type lungs. Expression of type I and type II BMP receptors, but not transforming growth factor-beta receptors, in the challenged BMPR2(+/-) and wild-type lungs showed a similar pattern of expression as that of endothelial markers. Apoptotic responses at 1 wk after MCT and Ad5LO challenge were also significantly greater in the BMPR2(+/-) lungs than the wild-type lungs. These data show that BMPR2(+/-) mice are more sensitive to MCT+Ad5LO-induced pulmonary hypertension than wild-type mice. Greater endothelial injury and an enhanced inflammatory response could be the underlying causes of the sensitivity and may work in concert with BMPR2 heterozygosity to promote the development of persistent pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552156      PMCID: PMC2519229          DOI: 10.1152/ajpheart.91519.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  53 in total

1.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.

Authors:  L Taraseviciene-Stewart; Y Kasahara; L Alger; P Hirth; G Mc Mahon ; J Waltenberger; N F Voelkel; R M Tuder
Journal:  FASEB J       Date:  2001-02       Impact factor: 5.191

2.  BMP type II receptor is required for gastrulation and early development of mouse embryos.

Authors:  H Beppu; M Kawabata; T Hamamoto; A Chytil; O Minowa; T Noda; K Miyazono
Journal:  Dev Biol       Date:  2000-05-01       Impact factor: 3.582

3.  Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1.

Authors:  R Hofer-Warbinek; J A Schmid; C Stehlik; B R Binder; J Lipp; R de Martin
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

4.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Authors:  Z Deng; J H Morse; S L Slager; N Cuervo; K J Moore; G Venetos; S Kalachikov; E Cayanis; S G Fischer; R J Barst; S E Hodge; J A Knowles
Journal:  Am J Hum Genet       Date:  2000-07-20       Impact factor: 11.025

5.  Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts.

Authors:  D Lyden; A Z Young; D Zagzag; W Yan; W Gerald; R O'Reilly; B L Bader; R O Hynes; Y Zhuang; K Manova; R Benezra
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

6.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

7.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

Authors:  J H Newman; L Wheeler; K B Lane; E Loyd; R Gaddipati; J A Phillips; J E Loyd
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

8.  Dynamic changes in apoptotic and necrotic cell death correlate with severity of ischemia-reperfusion injury in lung transplantation.

Authors:  S Fischer; A A Maclean; M Liu; J A Cardella; A S Slutsky; M Suga; J F Moreira; S Keshavjee
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

9.  Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.

Authors:  J R Thomson; R D Machado; M W Pauciulo; N V Morgan; M Humbert; G C Elliott; K Ward; M Yacoub; G Mikhail; P Rogers; J Newman; L Wheeler; T Higenbottam; J S Gibbs; J Egan; A Crozier; A Peacock; R Allcock; P Corris; J E Loyd; R C Trembath; W C Nichols
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

10.  Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity.

Authors:  Dong Liu; Jian Wang; Bernd Kinzel; Matthias Müeller; Xiaohong Mao; Reginald Valdez; Yongxing Liu; En Li
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

View more
  46 in total

Review 1.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

Review 2.  BMP signaling in vascular development and disease.

Authors:  Jonathan W Lowery; Mark P de Caestecker
Journal:  Cytokine Growth Factor Rev       Date:  2010-07-31       Impact factor: 7.638

3.  MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach.

Authors:  Victoria N Parikh; Richard C Jin; Sabrina Rabello; Natali Gulbahce; Kevin White; Andrew Hale; Katherine A Cottrill; Rahamthulla S Shaik; Aaron B Waxman; Ying-Yi Zhang; Bradley A Maron; Jochen C Hartner; Yuko Fujiwara; Stuart H Orkin; Kathleen J Haley; Albert-László Barabási; Joseph Loscalzo; Stephen Y Chan
Journal:  Circulation       Date:  2012-02-27       Impact factor: 29.690

4.  Redox Pioneer: Professor Joseph Loscalzo.

Authors:  Jane A Leopold
Journal:  Antioxid Redox Signal       Date:  2010-10-01       Impact factor: 8.401

5.  CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

Authors:  Tatiana Chirkova; Songbai Lin; Antonius G P Oomens; Kelsey A Gaston; Seyhan Boyoglu-Barnum; Jia Meng; Christopher C Stobart; Calvin U Cotton; Tina V Hartert; Martin L Moore; Assem G Ziady; Larry J Anderson
Journal:  J Gen Virol       Date:  2015-06-25       Impact factor: 3.891

Review 6.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch; Christophe Guignabert; Marc Humbert; Mark R Nicolls
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

7.  Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.

Authors:  Andrea L Frump; Arunima Datta; Sampa Ghose; James West; Mark P de Caestecker
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

8.  Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractility.

Authors:  Laura E Fredenburgh; Jun Ma; Mark A Perrella
Journal:  Trends Cardiovasc Med       Date:  2009-02       Impact factor: 6.677

9.  Right ventricular systolic pressure measurements in combination with harvest of lung and immune tissue samples in mice.

Authors:  Wen-Chi Chen; Sung-Hyun Park; Carol Hoffman; Cecil Philip; Linda Robinson; James West; Gabriele Grunig
Journal:  J Vis Exp       Date:  2013-01-16       Impact factor: 1.355

10.  The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice.

Authors:  Lakshmi Kugathasan; Julie Basu Ray; Yupu Deng; Effat Rezaei; Daniel J Dumont; Duncan J Stewart
Journal:  J Exp Med       Date:  2009-09-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.